|
M
Mon
|
T
Tue
|
W
Wed
|
T
Thu
|
F
Fri
|
S
Sat
|
S
Sun
|
|---|---|---|---|---|---|---|
|
0 events,
|
0 events,
|
0 events,
|
1 event,
Virtual Event
-
Virtual Event
The National Academies’ Board on Life Sciences is pleased to present two discussions - Bioeconomy of the Future and Changing Landscape of Life Science Research Laboratories – to explore critical and emerging issues with the bioeconomy and privately-sponsored basic life sciences research. The life sciences research landscape is changing rapidly as new investments in the |
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
1 event,
Featured
Virtual Event
Featured
Virtual Event
The George Mason University (GMU) Schar School of Policy and Government will host a Master’s and Certificate Virtual Open House on June 8, 2022 from 6:00 pm – 8:00 pm. The event will provide an overview of available master’s degree programs and highlight GMU’s world-class faculty and research. Admissions and student services staff will be on hand |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
1 event,
Virtual Event
-
Virtual Event
The VRBPAC committee will meet in open session on June 14, 2022 to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to children and adolescents 6 years through 17 years of age. FDA intends to make background material available to the public no later than |
1 event,
Virtual Event
-
Virtual Event
The VRBPAC will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 5 years of age, and also to discuss amending the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
1 event,
Virtual Event
-
Virtual Event
The VRBPAC will meet in open session on 28 June 2022 to discuss whether and how the SARS-CoV-2 strain composition of COVID-19 vaccines should be modified. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
